Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
Category: #health  | By Nikita Chaurasia  | Date: 2019-09-06 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
  • 12 patients with DME have enrolled into the study.
     
  • The results for the Phase 1 trial will be out by the end of 2019.

Oxurion NV, a biopharmaceutical firm involved in the development of innovative treatments to preserve vision of diabetic eye disease patients, has recently announced that it has completed enrolling patients in the Phase 1 trial for the evaluation of THR-687.

Apparently, Phase 1 trial, a multicenter, open-label, dose-escalation study would be evaluating the safety of one intravitreal injection of THR-687’s escalating dose levels (3) for treating patients suffering from diabetic macula edema (DME). A total number of 12 patients with the disease have been enrolled in the study trial.

For the record, THR-687 is a new pan-RGD integrin antagonist that is being developed as a possible treatment for patients suffering from diabetic eye disease. According to the preclinical demonstration, THR-687 is capable of targeting several aspects of retinal vascular disease like inflammation, neovascularization and vessel leakage. Results for the Phase 1 evaluation are expected to be out by the end of 2019.

Oxurion NV’s CEO, Patrik De Haes, MD, commented that the conclusion of patient recruitment portion means that the company is on track to unveil the results from the Phase 1 study before 2019 ends. After the recent Phase 1 with THR-149 exhibited positive results the company has been looking forward to its first THR-687 clinical data read-out which is the second VEGF pathway and independent molecule in the company’s innovative pipeline primarily focused on DME.

About the Oxurion:

Headquartered in Belgium, Oxurion focuses on developing treatments for diseases affecting the backside of the eye in patients. The company has engineered a diverse portfolio of drug candidates capable of modifying diseases that also include the treatment for diabetic eye disease, the main cause of blindness among working-age people around the world. It owns the global rights to Jetrea, also known as ocriplasmin, which is the only pharmacological vitreolysis drug to get approval for the treatment of symptomatic vitreomacular adhesion in the U.S.

 

Source Credit- https://www.oxurion.com/content/oxurion-completes-enrollment-phase-1-clinical-trial-evaluating-thr-687-novel-pan-rgd

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

PM Liz Truss to launch comprehensive review of UK’s visa policy

PM Liz Truss to launch comprehensive review of UK’s visa policy

By Nikita Chaurasia

Newly appointed Prime Minister Liz Truss is considering doing a complete review of Britain's visa system, as the nation struggles with severe labor shortages in vital industries. Business leaders across the UK have reportedly praised the decision...

UAE: Entrepreneurs and investors can benefit from visa reforms

UAE: Entrepreneurs and investors can benefit from visa reforms

By Nikita Chaurasia

The visa and business reforms by the UAE will open new prospects for investors, entrepreneurs, IT specialists, job seekers, and tourists, according to credible sources. This will reportedly benefit the region’s economic growth. Business Link...

Flipkart introduces new tech and design upgrades ahead of holiday season

Flipkart introduces new tech and design upgrades ahead of holiday season

By Nikita Chaurasia

Flipkart, India's indigenous online marketplace, is reportedly offering customers an improved shopping experience on its widely popular app. To better serve various client groups that are exploring e-commerce during the holiday season, Flipkar...